About AMP PD Overview
About the Accelerating Medicines Partnership
The Accelerating Medicines Partnership (AMP) is a public-private partnership between the National Institutes of Health (NIH), multiple biopharmaceutical and life sciences companies, and non-profit organizations.
Managed through the Foundation for the NIH (FNIH), AMP aims to identify and validate the most promising biological targets for therapeutics. Disease areas covered by AMP at the launch of this site include Alzheimer’s disease, type 2 diabetes, the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus) and Parkinson’s disease. Additional disease areas are being evaluated for addition to AMP.
The Accelerating Medicine Partnership in Parkinson’s Disease (AMP PD)
In 2018, through FNIH, an AMP partnership between the National Institute of Neurological Disorders and Stroke (NINDS), the Food and Drug Administration (FDA), GSK, Pfizer, Sanofi, Celgene, Verily and the Michael J. Fox Foundation (MJFF) was launched for Parkinson’s disease.
The research plan proposed for AMP PD encompasses a deep molecular characterization and longitudinal clinical profiling of PD patient data and biosamples with the goal of identifying and validating diagnostic, prognostic and/or disease progression biomarkers for Parkinson’s disease (PD).
A critical component of this partnership is broad sharing of the AMP Parkinson’s disease (AMP PD) data and analyses with the biomedical community to advance research in PD. AMP PD utilizes well characterized cohorts with existing biosamples and clinical data that were collected under comparable protocols and using common data elements.
The Release 1.0 cohorts include the Michael J. Fox Foundation (MJFF) and National Institutes of Neurological Disorders and Stroke (NINDS) BioFIND study, Harvard Biomarkers Study (HBS), the NINDS Parkinson's disease Biomarkers Program (PDBP), and MJFF Parkinson’s Progression Marker Initiative (PPMI). Release 2.0 adds the following cohorts; National Institute on Aging (NIA) International Lewy Body Dementia Genetics Consortium Genome Sequencing in Lewy body dementia case-control cohort (LBD), the MJFF LRRK2 Cohort Consortium (LCC), and the NINDS Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease, Phase 3 (STEADY-PD3).
Thank you to the all of the research participants who have contributed data through BioFIND, HBS, LBD, LCC, PDBP, PPMI, and STEADY-PD3, and to all of the study teams who have collected and managed these data. AMP PD appreciates your contributions, which are fundamental to AMP PD resource development.
AMP PD Steering Committee
Co-chairs
- Deb Babcock (NIH/NINDS)
National Institutes of Health - Pablo Sardi, Ph.D., Pharm. D.
Sanofi
Executive Committee Liaison
- Walter Koroshetz, M.D.
National Institutes of Health
NIH/OD Liaison
- Ellen Gadbois, Ph.D.
National Institutes of Health
Public Partner Representatives
- Billy Dunn, M.D.,
U.S. Food and Drug Administration - Gerald Podskalny, D.O.,
U.S. Food and Drug Administration - Lyn Jakeman, Ph.D., B.A.,
National Institutes of Health - Suzana Petanceska, Ph.D., B.S.,
National Institutes of Health
Private Funding Partner Representatives
- David Glazer, S.B.,
Verily - Ekemini Riley, Ph.D., B.A.,
Aligning Science Across Parkinson's - Guhan Nagapan, Ph.D.
GlaxoSmithKline - Irit Rapley, Ph.D., B.S.,
Celgene subsidiary of Bristol-Myers Squibb Company - Leslie Shinobu, M.D., Ph.D.,
Celgene subsidiary of Bristol-Myers Squibb Company - Michael Nagel, Ph.D., B.A.,
Pfizer - Richard Hargreaves, Ph.D., B.S.,
Celgene subsidiary of Bristol-Myers Squibb Company - Robert Bell, Ph.D., B.S.,
Pfizer - Shameek Biswas, Ph.D., M.Eng.,
Celgene subsidiary of Bristol-Myers Squibb Company - Todd Sherer, Ph.D., B.S.,
Michael J. Fox Foundation for Parkinson's Research - William Marks, Jr., M.D., M.S.,
Verily
Managing Partners
- David Wholley, M.Phil.
Foundation for the National Institutes of Health - Eline Appelmans, M.D., M.P.H., BMedSci
Foundation for the National Institutes of Health
AMP PD Consortium
Government
Food and Drug Administration (FDA)
National Institute of Neurological Disorders and Stroke (NINDS)
National Institute on Aging (NIA)
Industry
Nonprofit
Michael J. Fox Foundation (MJFF)
Data
MJFF LRRK2 Cohort Consortium (LCC)
Brigham and Women's Hospital/MGH Harvard Biomarkers Study
NINDS Parkinson's Disease Biomarkers Program
MJFF Parkinson’s Progression Markers Initiative
Managing
The FNIH, managing partner for AMP PD, is actively recruiting new industry and nonprofit partners. Inquiries about how your organization can join the partnership should be submitted to Eline Appelmans, Neuroscience Research Partnerships, at eappelmans@fnih.org